Search Results

AB Science SA is providing a summary of the live webcast held on March 4, 2024, giving an update on AB Science development.

AB Science SA reports its revenues for the year 2023 and provides an update on its activities.

AB Science SA (Euronext - FR0010557264 - AB) today announces that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a trending toward a negative opinion on the application for conditional marketing authorisation of masitinib in the treatment of amyotrophic lateral sclerosis (ALS), following an oral explanation held at the 28 May meeting of the CHMP.

AB Science SA (Euronext - FR0010557264 - AB) today announced that the European patent office has issued a Grant Decision for a patent relating to methods of treating severe mastocytosis with its lead compound masitinib (patent EP 3359195A1).

AB Science SA announced that it has postponed the publication of its 2023 annual financial report, initially scheduled for 30 April 2024, to give the auditors time to complete their audit work.

AB Science SA is providing a summary of the live webcast held on May 30, 2024, giving an update on the application for conditional marketing authorization of masitinib in the treatment of amyotrophic lateral sclerosis.